Introduction

Finding a new treatment for pancreatic cancer matters even more when the disease has already been treated and the remaining options become harder to choose.

That is where daraxonrasib (RMC-6236) has started getting attention. This targeted drug takes a different approach by interfering with RAS signaling, a pathway involved in the growth of many pancreatic cancers.

The interest became even stronger in 2026 after results from the Phase 3 RASolute 302 trial showed that daraxonrasib helped patients live longer than chemotherapy in a group of people with previously treated metastatic pancreatic ductal adenocarcinoma. FDA — Daraxonrasib (RASONQUE) approval and clinical evidence

But there is more to this drug than a promising headline. To understand where daraxonrasib may fit in pancreatic cancer treatment, it helps to look at what the molecule is, the chemistry behind how it works, what the clinical trials actually found, and what we still don’t know.

That is exactly what we will break down in this article.

Quick Summary

• Daraxonrasib (RMC-6236) is an FDA-approved targeted treatment for certain adults with metastatic pancreatic adenocarcinoma.
• It works by interfering with RAS signaling, a pathway involved in cancer-cell growth.
• The Phase 3 RASolute 302 trial studied daraxonrasib in people with previously treated metastatic pancreatic ductal adenocarcinoma.
• The trial found longer overall survival and progression-free survival with daraxonrasib compared with chemotherapy.
• These results do not mean daraxonrasib is a cure for pancreatic cancer.
• The drug’s approved treatment setting, safety profile, and remaining research questions are important when understanding where it fits in pancreatic cancer care.
• Its chemistry helps explain why researchers developed this approach, while the clinical evidence tells us whether that approach translates into meaningful patient benefit.

What Is Daraxonrasib?

Daraxonrasib, also known as RMC-6236, is an oral targeted drug that inhibits RAS proteins in their active, or RAS(ON), state. RAS is part of a signaling system that helps regulate cell growth and division.

What makes daraxonrasib particularly interesting is how it reaches its target. Instead of simply attaching to RAS on its own, the molecule works with an intracellular protein called cyclophilin A (CypA) to form a three-part complex involving CypA, daraxonrasib, and RAS. This complex interferes with RAS interactions needed for downstream signaling. Chemistry / tri-complex mechanism

From a drug-design perspective, this is important. Daraxonrasib is a noncovalent, macrocyclic molecule developed through structure-guided medicinal chemistry, allowing researchers to target multiple RAS variants rather than focusing on only one specific mutation. Structural interactions

In simple terms, daraxonrasib is not trying to destroy the cancer cell directly. It is designed to get in the way of a signaling system that cancer cells can depend on for continued growth.

That distinction is worth keeping in mind throughout this article: the chemistry and mechanism explain why researchers developed daraxonrasib, while the clinical trials tell us whether that strategy actually helps patients.

The Chemistry Behind Daraxonrasib

Daraxonrasib is interesting not simply because it targets RAS, but because of how it gets to RAS.

Unlike a conventional drug that binds directly to one clearly defined pocket on its target, daraxonrasib uses a different strategy. The molecule first interacts with an intracellular protein called cyclophilin A (CypA). This creates a binding surface that allows the drug–CypA complex to engage the active form of RAS and form a three-part structure known as a tri-complex.

A noncovalent approach to RAS

Daraxonrasib is a noncovalent inhibitor. In simple terms, it does not rely on forming a permanent chemical bond with RAS. Instead, a collection of weaker interactions helps hold the drug in the right position.

Structural studies have identified several of these interactions, including hydrogen bonds, hydrophobic interactions, π–π stacking, and van der Waals interactions involving regions of RAS known as Switch I and Switch II. Together, these interactions help create the binding arrangement needed to interfere with RAS signaling.

This is where the chemistry becomes especially interesting: the drug is not working alone. CypA effectively helps create the environment in which daraxonrasib can recognize active RAS. Researchers describe this type of approach as a tri-complex inhibitor or molecular-glue-like strategy.

Why the structure matters

Daraxonrasib is a macrocyclic molecule, a structural feature that was developed through structure-guided medicinal chemistry. Its design was optimized to interact with conserved features across multiple RAS variants and isoforms rather than being limited to one specific mutant form.

That broader design is important in pancreatic cancer, where RAS alterations are extremely common. But it also illustrates an important principle of drug development: a clever molecular design is only the beginning. The real question is whether that chemistry translates into meaningful benefit for patients.

And that is where the clinical trial evidence becomes more important than the molecular structure alone.

How Does Daraxonrasib Work?

To understand daraxonrasib, it helps to think of RAS as part of a communication system inside the cell.

RAS proteins help transmit signals that tell cells when to grow, divide, and respond to their surroundings. In some cancers, changes in the RAS pathway can keep these growth signals switched on when they should normally be controlled.

Daraxonrasib is designed to interfere with RAS in its active, or RAS(ON), state. By binding through its interaction with cyclophilin A, it can disrupt interactions between active RAS and proteins involved in downstream signaling. The goal is to reduce the signals that encourage cancer cells to continue growing and surviving.

This approach is particularly interesting in pancreatic cancer because KRAS alterations are common in pancreatic ductal adenocarcinoma. Instead of trying to attack every cancer cell in the same way, researchers are targeting a signaling dependency that many of these tumors share.

But there is an important distinction: blocking a cancer pathway in a laboratory or molecular model does not automatically translate into longer survival for patients. That is why the clinical trial evidence matters so much.

The chemistry tells us how daraxonrasib can interact with RAS. The biology explains why that interaction might slow cancer growth. The clinical trials ultimately tell us whether that strategy makes a meaningful difference in people.

What Do the Clinical Trials Actually Show?

The early studies of daraxonrasib gave researchers an important signal: targeting active RAS could produce measurable antitumor activity in people with previously treated pancreatic cancer. In an earlier Phase 1/2 study, daraxonrasib showed antitumor activity in patients with RAS-mutated pancreatic ductal adenocarcinoma, providing evidence that supported further clinical development. Phase 1/2 daraxonrasib study

The bigger test came with RASolute 302, a Phase 3 international trial comparing daraxonrasib with chemotherapy in people with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). Patients were randomly assigned to receive either once-daily oral daraxonrasib or chemotherapy selected by the treating investigator. RASolute 302 Phase 3 trial

A total of 500 patients were enrolled: 248 received daraxonrasib and 252 received chemotherapy. Most participants — 91.8% — had RAS G12 mutations. The overall study population also included patients with RAS G13 or Q61 mutations and patients in whom no RAS mutation was identified.

The trial was designed to answer two major questions: Does daraxonrasib help patients live longer, and does it keep the cancer from progressing for longer? Both measures favored daraxonrasib.

In the overall population, median overall survival was 13.2 months with daraxonrasib versus 6.7 months with chemotherapy. Median progression-free survival was 7.2 months versus 3.6 months, respectively. The hazard ratio for death was 0.40, while the hazard ratio for disease progression or death was 0.49. Both results were statistically significant.

These numbers are important, but the numbers alone do not tell the whole story. The next question is what this size of benefit actually means for someone with previously treated metastatic pancreatic cancer — and where the trial’s limitations begin.

RASolute 302 Phase 3 Trial: What Were the Results?

The most important evidence for daraxonrasib comes from RASolute 302, a randomized Phase 3 trial in people with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). The study compared daraxonrasib with investigator-selected chemotherapy and evaluated both overall survival and progression-free survival. RASolute 302 Phase 3 trial

Overall survival

The clearest benefit was seen in overall survival (OS). Across the overall study population, median overall survival was 13.2 months with daraxonrasib compared with 6.7 months with chemotherapy. The hazard ratio for death was 0.40, meaning the observed risk of death was about 60% lower with daraxonrasib during the study period.

That is a substantial difference at the population level. But median survival is not a prediction for an individual patient: some people will live longer than the median, while others will not.

Progression-free survival

Daraxonrasib also improved progression-free survival (PFS) — the length of time before the cancer progressed or the patient died.

Median PFS was 7.2 months with daraxonrasib versus 3.6 months with chemotherapy in the overall population. Among patients with RAS G12 mutations, median PFS was 7.3 versus 3.5 months, respectively.

Together, the OS and PFS results suggest that the benefit was not limited to delaying tumor progression; patients in the studied population also lived longer.

What does the RAS result mean?

Another important point is that daraxonrasib was developed as a multi-selective RAS(ON) inhibitor, rather than a treatment aimed at only one specific KRAS mutation. RASolute 302 therefore provides clinical evidence for a broader RAS-targeting strategy in metastatic pancreatic cancer.

The trial results helped support the FDA’s August 26, 2026 approval of daraxonrasib (RASONQUE) for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. FDA — Daraxonrasib approval

The numbers are impressive, but they still need context. A median survival of 13.2 months does not mean every patient taking daraxonrasib will live for 13.2 months, and it does not mean the drug cures metastatic pancreatic cancer. The next question is what these results actually mean for patients.

Daraxonrasib Trial Results: What Do the Numbers Actually Mean?

Clinical trial numbers can look impressive, but they become much more useful when you understand what they actually measure.

In RASolute 302, median overall survival was 13.2 months with daraxonrasib versus 6.7 months with chemotherapy. In simple terms, median survival is the point at which half of the patients had lived longer and half had not. It does not mean that every patient taking daraxonrasib will live for exactly 13.2 months. RASolute 302 Phase 3 trial

The hazard ratio for death was 0.40. This is a relative measure, not a prediction of an individual patient’s lifespan. Broadly speaking, a hazard ratio of 0.40 means the observed rate of death was about 60% lower in the daraxonrasib group than in the chemotherapy group during the study period.

Progression-free survival tells a different part of the story. Median PFS was 7.2 months with daraxonrasib versus 3.6 months with chemotherapy. It measures the time before the cancer progressed or the patient died, rather than survival alone.

So the important point is not simply that one number was larger than another. Both overall survival and progression-free survival favored daraxonrasib, showing benefit across two clinically relevant measures.

There is still an important limitation to keep in mind: these are population-level trial results. Individual outcomes can vary considerably depending on factors such as disease characteristics, previous treatments, overall health, and how the cancer responds to therapy.

That is why the RASolute 302 results are best understood as evidence that daraxonrasib can improve outcomes for an appropriate treatment population — not as a guarantee of the same result for every person with pancreatic cancer.

Who Was Studied in the Daraxonrasib Trial?

The RASolute 302 trial focused on people with metastatic pancreatic ductal adenocarcinoma (PDAC) whose disease had progressed after previous treatment. This is important because the trial was not testing daraxonrasib as a first treatment for newly diagnosed pancreatic cancer.

The study included 500 patients, with participants randomly assigned to daraxonrasib or investigator-selected chemotherapy. The majority had RAS G12 mutations, reflecting the biology of the disease being studied.

The FDA’s 2026 approval is also specific. RASONQUE (daraxonrasib) is approved for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.

That distinction matters. A drug can show strong results in a specific clinical setting without those results automatically applying to every type or stage of pancreatic cancer.

For anyone considering daraxonrasib, the appropriate treatment setting, previous therapy, overall health, tumor characteristics, and the treating team’s assessment all matter.

Daraxonrasib Side Effects and Safety

A promising cancer treatment still has to be judged by its safety profile. With daraxonrasib, the question is not simply whether it can slow cancer growth, but whether its potential benefit is reasonable compared with the risks of treatment.

In the RASolute 302 trial, adverse events were common in both treatment groups, which is expected in people receiving therapy for advanced pancreatic cancer. The safety profile of daraxonrasib was considered manageable, although some patients experienced adverse effects serious enough to require dose interruption, reduction, or discontinuation.

The FDA prescribing information identifies important adverse reactions associated with RASONQUE, including diarrhea, nausea, fatigue, decreased appetite, vomiting, abdominal pain, and weight loss. Laboratory abnormalities can also occur during treatment.

Some adverse reactions require particular attention. For example, significant gastrointestinal effects can lead to dehydration or other complications if they are not managed appropriately. The prescribing information therefore includes recommendations for monitoring and dose modification when clinically significant toxicity occurs.

This is one area where the chemistry-to-clinic connection becomes important. A drug can be highly selective for a biological target and still affect normal tissues or physiological processes. Targeted therapy does not mean side-effect-free therapy.

For patients, the practical takeaway is simple: daraxonrasib’s benefit has to be considered alongside its individual risks, other medications, existing health problems, and ability to tolerate treatment. Decisions about starting, continuing, or modifying therapy belong with the treating oncology team.

Is Daraxonrasib FDA Approved?

Yes. Daraxonrasib is now FDA approved.

On August 26, 2026, the U.S. Food and Drug Administration approved RASONQUE (daraxonrasib) for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.

The recommended dose is 300 mg taken orally once daily, continued until the cancer progresses or treatment becomes too toxic to continue.

The approval was supported by the results of RASolute 302, the randomized Phase 3 trial discussed earlier. In the overall study population, daraxonrasib improved both overall survival and progression-free survival compared with chemotherapy, and the trial also showed a higher objective response rate with daraxonrasib.

This approval is important, but its wording matters. FDA approval does not mean daraxonrasib is approved for every person with pancreatic cancer. The indication is specifically for metastatic pancreatic adenocarcinoma in the treatment settings described above.

So, as of August 2026, daraxonrasib has moved beyond the investigational stage and is an FDA-approved treatment option for an appropriate group of adults with metastatic pancreatic cancer.

Daraxonrasib vs Chemotherapy

Daraxonrasib and chemotherapy take very different approaches to treating cancer.

As a targeted therapy, daraxonrasib is designed to interfere with active RAS signaling, while conventional chemotherapy works more broadly against rapidly dividing cells. In RASolute 302, the two approaches were compared directly in people with previously treated metastatic pancreatic cancer.

The results favored daraxonrasib in the trial population, with longer overall survival and progression-free survival. But the important point is not simply that one treatment produced better numbers than the other. The comparison was made in a specific group of patients and under a specific treatment setting.

That means the results should not be interpreted as “targeted therapy is always better than chemotherapy.” Chemotherapy remains an important part of pancreatic cancer treatment, and the appropriate option depends on factors such as previous treatment, disease characteristics, overall health, and treatment goals.

The more useful takeaway is that daraxonrasib adds a new treatment approach for an appropriate group of patients rather than making existing pancreatic cancer treatments obsolete.</p>

What We Still Don’t Know About Daraxonrasib

The 2026 results are important, but they do not answer every question about daraxonrasib.

First, the strongest clinical evidence comes from a specific treatment setting: adults with metastatic pancreatic adenocarcinoma who have received previous treatment or are not candidates for multiagent systemic therapy. We should therefore not assume that the same benefit applies to earlier-stage pancreatic cancer or to every patient with a RAS alteration.

Second, cancer cells can adapt. Even when a treatment successfully blocks an important signaling pathway, tumors may eventually develop or use alternative mechanisms that allow them to continue growing. Understanding how resistance develops with RAS-targeted therapies remains an important area of research.

There is also a practical question that clinical trials cannot completely answer: how will daraxonrasib perform across the broader population of patients treated in everyday oncology practice? Trial participants are carefully selected and monitored, while real-world patients can have more varied health conditions, previous treatments, and medication combinations.

Finally, FDA approval answers an important regulatory question, but it does not mean every scientific question has been settled. Future research will help clarify how best to use daraxonrasib, which patients are most likely to benefit, and how it might fit alongside other emerging treatments.

That is the more useful way to view daraxonrasib in 2026: a significant new treatment option, but not the end of the pancreatic cancer treatment story.

Frequently Asked Questions

Is daraxonrasib FDA approved for pancreatic cancer? +

Yes. The FDA approved RASONQUE (daraxonrasib) in August 2026 for certain adults with metastatic pancreatic adenocarcinoma, including patients who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.

What does daraxonrasib target? +

Daraxonrasib targets active RAS (RAS-ON) signaling through a tri-complex involving daraxonrasib, cyclophilin A, and RAS. This approach is designed to interfere with signaling that can support cancer-cell growth.

What did the RASolute 302 trial find? +

The Phase 3 trial found longer median overall survival and progression-free survival with daraxonrasib compared with chemotherapy in the studied population. Median overall survival was 13.2 months versus 6.7 months.

Does daraxonrasib cure pancreatic cancer? +

No. The available evidence does not show that daraxonrasib cures metastatic pancreatic cancer. It is a treatment that can improve outcomes in an appropriate patient population.

What are the main side effects of daraxonrasib? +

Important adverse reactions reported with RASONQUE include rash, diarrhea, stomatitis, nausea, fatigue, vomiting, abdominal pain, edema, decreased appetite, and hemorrhage. The drug also has important warnings and precautions that may require monitoring and dose adjustments.

Is daraxonrasib a chemotherapy drug? +

No. Daraxonrasib is a targeted therapy that interferes with RAS signaling, while conventional chemotherapy generally works more broadly against rapidly dividing cells.

Bottom Line

Daraxonrasib marks an important step in targeting RAS-driven pancreatic cancer. The RASolute 302 results showed a meaningful survival benefit in a specific group of patients, and the FDA approval in 2026 has moved the drug from an investigational therapy to an approved treatment option.

But the most important takeaway is balance: daraxonrasib is a significant new treatment option, not a cure for pancreatic cancer. Its chemistry explains why the drug is promising, while the clinical evidence tells us where it has actually helped patients. For now, the best way to view daraxonrasib is as a new tool in the pancreatic cancer toolbox — not the whole toolbox.